Login to Your Account


John Oyler Aims To Build China’s Genentech via Beigene

By Lynn Yoffee
Executive Editor

Wednesday, November 27, 2013

BEIJING – Just a few days after Beigene Co. Ltd.’s CEO and co-founder John Oyler signed a second sizable deal with the Merck Serono arm of Merck KGaA – the up-front payments undisclosed, but with a promise of almost $500 million if all milestones are achieved in both – he admitted the cash removes a layer of stress: “Maybe you sleep better at night, but it’s business as usual. The deal with Merck doesn’t change the way you work or the passion.”

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription